Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.
Pepper
R J
RJ
Fabre
M A
MA
Pavesio
C
C
Gaskin
G
G
Jones
R B
RB
Jayne
D
D
Pusey
C D
CD
Salama
A D
AD
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015267:Churg-Strauss Syndrome / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015848:Interleukin-5 / Q000096:biosynthesis*; D008297:Male; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D015848:Interleukin-5; D000069283:Rituximab